Advicenne launches a share buyback program

Advicenne, the pharmaceutical company specializing in rare kidney diseases, announced the launch of a share buyback program. Approved at the general meeting of May 14, 2024, this program allows the repurchase of up to 10% of the share capital for 18 months. The board of directors validated this decision immediately after the meeting.

The buyback could be done in several phases, even using derivative instruments if necessary, while respecting the regulations in force. The maximum price per share is set at 21 euros, with a total budget of 3 million euros. Advicenne also confirms the intervention of an investment services provider to manage this buyout.